- Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
- January 10, 2026
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- January 05, 2026
- Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
- December 18, 2025
- PADCEVTM Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- December 17, 2025
- Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
- December 16, 2025
- Pfizer Declares First-Quarter 2026 Dividend
- December 12, 2025
- TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
- December 10, 2025
- Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
- December 09, 2025
- HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
- December 06, 2025
- Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance
- December 01, 2025
- U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
- November 21, 2025
- Pfizer Completes Acquisition of Metsera
- November 13, 2025
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- November 12, 2025
- Pfizer Responds to Delaware Chancery Court Ruling
- November 05, 2025
- Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement
- October 31, 2025
- Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
- October 31, 2025
- Pfizer Addresses Proposal for Metsera
- October 30, 2025
- XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
- October 19, 2025
- Pfizer's BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
- October 19, 2025
- PADCEVTM Plus KEYTRUDATM, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
- October 18, 2025
- TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
- October 14, 2025
- Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025
- October 13, 2025
- Pfizer Declares Fourth-Quarter 2025 Dividend
- October 09, 2025
- Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
- September 30, 2025
- Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025
- September 25, 2025
- Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
- September 23, 2025
- Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
- September 22, 2025
- Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
- September 08, 2025
- Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
- August 27, 2025
- PADCEVTM Plus KEYTRUDATM Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
- August 12, 2025
- Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance
- August 05, 2025
- Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
- July 25, 2025
- Pfizer Completes Licensing Agreement with 3SBio
- July 24, 2025
- XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
- July 10, 2025